.png){kind=icon}
.png){kind=icon}
Return
Repurposing tirbanibulin as an orally active E2-targeting entry inhibitor against Chikungunya virus
.png){kind=icon}
PRE
AI
J
Y
Y
W
S
H
Y
F
P
DOI：10.1111/bph.70642.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Chikungunya virus (CHIKV) causes severe acute and chronic disease, yet no approved specific antiviral treatment exists. To rapidly identify potential treatments, we aimed to screen an FDA-approved drug library for inhibitors of CHIKV infection. Tirbanibulin, a dual-microtubule polymerization and Src kinase inhibitor, was assessed for its potential anti-CHIKV activity.
Keywords:
antiviral therapy
Chikungunya virus
drug repurposing
E2-targeting
tirbanibulin (KX-01, KX2-391)
viral entry inhibitor
Journal
IF:
7.7
Papers:
1.4W
Citations:
3.7W
Organization
Cited Papers